• Thorsten Umland, PhD

    Head of Innovation & Development Personal Care Unit
    Bayer Consumer Health

Thorsten is responsible for Innovation & Development for Personal Care at Bayer, which includes the Suncare, Skincare and Footcare businesses. Prior to that, he was Head of Business Development & Licensing for the Consumer Health Division. In this function, he drove Bayer’s recent acquisitions of Merck Consumer Health, Dihon Pharmaceuticals, and Steigerwald.

Thorsten is a molecular biologist by training and started his career as a scientist in BASF’s Pharma Division He later transitioned into business development when he joined Schering AG, where he worked both at the company’s research site in California, and at the company’s US headquarters in New Jersey. After Bayer acquired Schering, Thorsten relocated to Leverkusen, Germany where he became Vice President of Corporate Development and Head of HealthCare Strategy at Bayer AG.

Barry Clare v1
  • Barry Clare

    Clarat Partners

Barry is a pioneering healthcare business leader with extensive experience in the healthcare industry sector. He has held a number of top roles at leading international companies and has a proven track record in developing and implementing strategy in healthcare, retail consumer products and financial services.

Barry created Boots Healthcare International, the international ‘over the counter’consumer healthcare business of the Boots Company PLC; through Barry’s leadership the business became the fastest growing ‘over the counter company’in Europe. During his time as a board member of Boots, Barry was responsible for the global expansion of international brands including Nurofen, Strepsils and Clearasil. Following his career at Boots, Barry has been Chairman of a number of successful, pioneering healthcare companies that have brought several ground breaking innovations to the NHS. Barry’s portfolio of innovative healthcare solutions include: e-health business, diagnostics tests and medicines development.

Yvan v1
  • Yvan Vindevogel

    Excecutive Chairman, Vemedia Consumer Health CEO, Damier group
    Damier Group

Yvan Vindevogel (Pharmacist and Cosmetologist), has a wealth of experience in consumer healthcare. He was the founder and CEO of Omega Pharma, Vemedia Pharma and many other Consumer Healthcare companies.
With his investment vehicle Damier, he is currently exploring, investing or co-investing, together with some important private equity companies, in (European) companies active in the branded consumer health sector, and acquiring well-established brands or innovative technologies.

Gian headshot v1
  • Gian Trepp

    Founder and Owner
    GBT Pharma

Gian launched GBT Pharma in June 2010 bringing with him over 20 year’s experience in building and managing international markets for healthcare brands.

With a proven track record in the consumer healthcare industry, Gian’s practical experience ensures he is well versed in managing and securing access to new markets in addition to driving product development.

Gian’s previous roles have included a decade of senior positions for Vifor Pharma Ltd, a subsidiary of Swiss healthcare group Galenica.

As head of the company’s oral iron franchise, Gian successfully oversaw launches of leading products into Western Europe and North America.

Gian also headed up the company’s Consumer Healthcare International Division with responsibility for all international markets.

Success stories

  • Gian managed successful international market development for consumer healthcare brands including Similasan eye care, Parsenn Products and Axiomedic
  • Leading Vifor Pharma’s therapeutic oral iron division, Gian oversaw the launch of Maltofer in over 80 countries achieving local sales of more than 200 million Swiss francs and 11% market share
  • As head of Vifor Pharma Consumer International, Gian had full P&L responsibility for all international markets and 65 employees. During his tenure, sales increased from 2.8 million Swiss Frances to over 45 million

Education & Professional Qualifications

Gian holds a Ph.D in Biochemistry from The Swiss Federal Institute of Technology in Zurich (ETHZ) and an MBA in general management from St Thomas University, USA.

  • Andrea Ponti

    Executive Partner and Founder
    GHO Capital

Andrea has 30 years of investment banking experience, focusing on healthcare since 1996. He created both JP Morgan’s and Goldman Sachs’ European investment banking healthcare franchises, advising on some of the most significant Mergers and Acquisitions for leading pharmaceutical, medical device and hospital companies but also advising emerging companies and private equity on M&A and debt or equity financing. Over the last five years he was Vice Chairman of European Investment Banking and Global co-head of Healthcare at J.P. Morgan. Prior to that Andrea was at Goldman Sachs, where he was Partner, Managing Director, Head of European Healthcare, Consumer and Retail and also Co Global Head of Healthcare and covered a variety of roles during his time at the firm including member of the firm-wide Commitments Committee. Andrea sits on the board of Cell Medica and holds a BA in Economics with Highest Honours from the University of North Carolina at Chapel Hill, where he is also a member of the Arts and Sciences Foundation Board of Directors

Rupert Headshot v2
  • Rupert Hill

    Managing Director

Mr. Hill joined Greenhill in 2012 and focuses on the healthcare sector. He has recently advised on landmark transactions such as Teva’s USD42bn acquis ition of Allergan’s generics business and Actavis’ USD28bn acquisition of Forest Laboratories and USD8bn acquisition of Warner Chilcott. He previously served as Head of Healthcare for EMEA and Asia-Pacific at Bank of America Merrill Lynch, having joined Merrill Lynch in 2000. During his twelve years there he advised on some of the largest healthcare transactions in Europe and the Emerging Markets. Prior to joining Merrill Lynch, he spent five years at Charterhouse Bank and three years at Price Waterhouse, where he qualified as a Chartered Accountant. Rupert speaks fluent French and Spanish.

Eric Desai
  • Eric Desai

    Greenhouse Capital Partners

Eric is an experienced growth equity and venture capital investor, with a background in consumer products and services. Prior to joining Greenhouse, Eric was a Vice President at Robin Lane Capital, a consumer goods and services growth equity investment firm. Eric has also held Corporate Strategy and Product Development roles at Revolution Foods and Philips, focusing on Food, Consumer Lifestyle and Healthcare. Eric spent his early career in the M&A Group at PricewaterhouseCoopers in the Netherlands.

Eric holds a BS in Finance and Accounting from the University of Arizona, and an MBA from UC Berkeley’s Haas School of Business.


  • Inga Deakin

    Healthcare Ventures Associate
    Imperial Innovations

Inga is an Associate in the Healthcare Ventures team, specialising in investments across medical devices, therapeutics, diagnostics, and healthcare, including digital health. She is currently a Director at Puridify and Ieso Digital Health and a board observer at Veryan Medical and Precision Ocular Devices.

Previously she worked in business development and technology transfer at the London Bioscience Innovation Centre/Royal Veterinary College in London, commercializing research, sourcing and building industry collaborations. She completed a DPhil and MSc in Neuroscience from the University of Oxford, sponsored by the Wellcome Trust, developing translational models of disease using a range of molecular biology, genetics, electrophysiology, imaging and behavioural techniques. Her first degree was Natural Sciences from the University of Cambridge

  • Roger Gunnarsson

    Managing Director, Global Healthcare Investment


Roger Gunnarsson is a Managing Director in Jefferies Global Healthcare Investment Banking team. He is based in London and is responsible for a select group of larger therapeutics and some pure play OTC companies, as well as the firms European medical technology and diagnostics franchise.
Mr Gunnarsson has 21 years experience as an investment banker, the latter 14 of which have been focused solely on healthcare. Prior to joining Jefferies, he ran his own independent consultancy/advisory boutique and before that he was head of Barclays Healthcare Investment Banking team in the EMEA region (2009-13). He has also worked for Lehman Brothers, Merrill Lynch, General Electric and SBC Warburg (now UBS).
Over the years, Mr Gunnarsson has transacted for a host of companies, including GSK, Roche, Novartis, Pfizer, Molnlycke, Dako, UCB, CSL, Cosmo Pharma, Thermo Fisher and others. Mr Gunnarsson has an MSc degree in economics and business administration (finance focus) from the Stockholm School of Economics.


Rajesh headshot v1
  • Rajesh Mishra

    Vice President R&D Consumer OTC
    Johnson & Johnson

Rajesh (Raj) Mishra M.D., PhD, currently serves as Vice President R&D Consumer OTC and Head of OTC R&D for the EMEA region based out of the UK. Raj has a wealth of U.S. and global industry experience with broad experience in OTC medicines across multiple therapeutic categories. Raj joined Johnson & Johnson Family of Consumer Companies as Vice President Medical and Clinical Affairs, Global OTC in March, 2014. In this role Raj served on the McNeil Management Board, and also on the Global OTC leadership team. Raj was responsible for providing medical and clinical oversight across the entire range of OTC therapeutic areas including pain, upper respiratory/allergy, digestive health, smoking cessation, and RX to OTC switch.

Prior to his current role at Johnson & Johnson, Raj was Vice President and Global Head Medical Affairs & Clinical Research at Merck Consumer Care. At Merck, Raj led the Global Medical and Consumer Science Innovation Center of Excellence, and had responsibility for Medical Affairs, Clinical Operations and the Consumer Science Research Center, providing strategic direction, operational, medical/clinical leadership and management for multiple franchises. Before joining Merck, Raj spent 5+ years in various roles within Medical Affairs and R&D product development at GlaxoSmithKline serving as Vice President R&D for Weight Control and Smoking Cessation and Head of Medical Affairs North America.

Raj earned his Doctor of Medicine (MD) and Masters in General Surgery (MS) at B.J. Medical College, Pune University in India. Raj also holds a Doctor of Philosophy (PhD) In Pharmacology from Southern Illinois University Carbondale School of Medicine and an Advanced Management Program Certification from Wharton, University of Pennsylvania.

Sid Full Photo v2
  • Siddhart Nahata

    Managing Director, Healthcare Investment Banking
    Morgan Stanley

15 years Investment Banking / 11 years at Morgan Stanley
• Joined Morgan Stanley’s Investment Banking Group in London in 2005 after spending 4 years at JPMorgan
• Worked in London, New York and Mumbai focused on biopharmaceuticals (Large Cap, Specialty and Generics) and OTC
• Graduate degree in Accounting and Finance from the University of Warwick and a post-graduate degree in Accounting and Finance from the London School of Economics

Deal Experience:
–KKRs acquisition of LGC–Sale of Roxane Laboratories to Hikma plc ($2.65Bn)
–Spin-off of Indivior from Reckitt Benckiser plc
–Sale of Omega Pharma to Perrigo (EUR 3.6Bn)
–AstraZeneca’s defence against Pfizer (~$120Bn)
–Mylan’s acquisition of Agila Specialties ($1.6Bn)–Cipla’s acquisition of Cipla Medpro South Africa ($550MM)
–Reckitt / Bristol-Myers Squibb LatAm OTC
–Pronova’s sale to BASF (NOK 5.0Bn)–Reckitt’s acquisition of Schiff Nutrition ($1.4Bn)
–AstraZeneca’s acquisition of Ardea Biosciences ($1.3Bn)
–Sale of Paras Personal Care brands by Reckitt Benckiser to Marico
–Altor’s acquisition of Orchid Orthopaedics–Sale of Paras Pharma to Reckitt Benckiser ($725MM)
–Parkway Holdings / Khazanah ($3.7Bn)
–Acquisition of Orchid Injectables by Hospira ($400MM)
-Acquisition of Piramal Healthcare by Abbott ($3.7Bn)
–Sale of Cambridge Antibody Technologies to AstraZeneca (£702MM)
–Fresenius’ acquisition of Dabur Pharma ($365MM)–Bausch & Lomb’s sale to Warburg Pincus ($4.6Bn)
–Nycomed’s acquisition of Bradley Pharmaceuticals ($346MM)
–Shire’s acquisition of New River Pharmaceuticals ($2.6Bn)
–Nycomed’s acquisition of Altana Pharma (EUR 4.2Bn)
–Sale of Cambridge Antibody Technology to AstraZeneca (GBP 702MM)
–Sale of Medi-Partenaires to Investor Group (EUR 323MM)
–IPO of Grifols, LifeCycle Pharma
–Exchangeable Bond Offering for the Govt. of Hungary
–Financings for AstraZeneca, GSK, Mylan, AstraZeneca, Shire, Nycomed, Bristol Myers and Schering-Plough

Kevin Foley Photo 2016
  • Kevin Foley

    Vice President Worldwide Business Development
    Pfizer Consumer Healthcare

  • Francine Nieto

    Global Consumer Health Offering Director

With over 20 years experience in the healthcare industry, Francine has held both local and international (pan-European and global) offering development, sales, marketing and general management roles in QuintilesIMS.
Francine’s current focus is expansion of QuintilesIMS’s solutions for Consumer Health companies. By combining critical information with innovative technology, supported by advisors with deep industry expertise, these solutions help clients:

  • improve interaction with their customers via different channels
  • identify and pursue business opportunities
  • achieve efficient operations

A graduate in languages and education, before joining QuintilesIMS, Francine was Editor of OTC News and Consultant at Nicholas Hall & Co.

Maayke, Headshot
  • Maayke Fluitman

    Managing Partner SelfCareFactorY; owner care2create

Maayke received her Master in Pharmacy from the Department of Pharmaceutical Sciences at the University of Utrecht, Netherlands. She has an extensive experience in pharmacy, primary care and self care. After gaining four years’ experience working as a community pharmacist she worked for over 10 years for Alliance Healthcare, where, in her final role as Pharmacy Governance Manager she was responsible for Clinical Governance Program of the pharmacy chain. In 2008 she joined the board of the Royal Dutch Association of Pharmacists (KNMP), of which she was vice-president for four years. She currently is president of the Department of Pharmacists, Medicine & Society at the KNMP.

She started her own business, care2create, to be able to create and launch new concepts in healthcare, wellness and self care. Maayke is also associate partner of Altuïtion, a marketing research company specialised in customer journeys and engagement engineering

Her interest and experience in self care led to strategic involvement on policy level, European as well as International, on creating standards and strategy to develop self care further.
Together with Jan Smits, she owns the SelfCareFactorY, an independent platform on trends and solutions in self care. The aim of this platform is to share best practice in self care and to facilitate the exchange of ideas and to sharpen opinions


Clive Allison Headshot
  • Clive Allison

    Innovation Director

Dr Clive Allison is Global Director of Open Innovation at Unilever one of the world’s most successful consumer goods companies. Around 200 million times a day, someone somewhere chooses a Unilever product across our Home Care, Personal Care, Foods and Refreshment product categories. At Unilever our purpose is to make sustainable living commonplace and through Open Innovation we give people and organisations the confidence to build the transformational winning partnerships required to deliver to that purpose.

Clive holds a PhD from the University of Cambridge and has more than 20 years of experience in leadership roles in R&D and Innovation across the Home and Personal Care product categories. Clive has a passion for disruptive innovation that makes a real difference in the World and in that context he leads the establishment of transformational innovation partnerships connecting Corporate, SME, Academic and Public partners to deliver business and societal impact.

Paul headshot v1
  • Paul Valdez

    Valdez Consulting

Paul has worked in the consumer healthcare sector for over 30 years. His career has included senior roles with GlaxoSmithKline (GSK), Bristol-Myers Squibb and Reckitt & Colman (now Reckitt Benckiser). In 2011 Paul founded Valdez Consulting, a marketing and business development consultancy that helps clients to grow through geographic expansion and marketing excellence